
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.

During a case-based roundtable event, Ashley Evan Ross, MD, PhD, reviewing therapeutic options for a patient with metastatic hormone-sensitive prostate cancer.

During a live virtual event, Edwin M. Posadas, MD, discussed the use of cabazitaxel in patients with metastatic castration-resistant prostate cancer with participants. This is the second of 2 articles based on this event.

Results from the phase 3 TRITON3 study show that rucaparib improves survival in multiple metastatic castration-resistant prostate cancer populations.

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

During a live virtual event, Edwin M. Posadas, MD, discussed patient factors for choosing the type of therapy to use after progression on androgen receptor therapy and chemotherapy with participants.

Positive findings were reported from the phase 2 ARNEO trial during the European Association of Urology Congress 2022.

In an interview with Targeted Oncology, Fred Saad, MD, FRSC, discussed key biomarkers for prostate cancer and findings from a biomarker analysis of the phase 3 PROpel clinical trial.

Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.

No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.

The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.

Androgen-deprivation therapy with the addition of apalutamide was effective when used in patients with high-risk biochemically relapsed prostate cancer.

Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.

Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.

An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Alan H. Bryce, MD, discussed the case of a patient with high-volume, hormone-naive metastatic prostate cancer.

During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.

Olaparib in combination with abiraterone and prednisone, or prednisolone may soon be an FDA-approved treatment for adult patients with metastatic castration-resistant prostate cancer.

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.

During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Closing out their discussion on novel treatment approaches in prostate cancer, experts consider future strategies and remaining unmet needs in this setting.

A brief discussion on the importance of germline/somatic BRCA1 and BRCA2 mutations in metastatic CRPC, accompanied by practical advice on genetic testing.


































